Focus on Clozapine

References

• Honigfield G. Effects of the Clozapine National Registry system on incidence of death related to agranulocytosis. Psych Servs 1996;47:52–6
   Google Scholar
• Walker et al. Mortality in current and former users of clozapine. Epidemiol 1997;8:671–7
   PubMed Web of Science ®Google Scholar
• Meltzer HY et al. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia; impact on risk benefit assessment. Am J Psych 1995;152:183–90
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfield G, Singer J et al. Clozapine for the treatment-resistant schizophrenic; a double blind comparison with chlorpromazine (Clozaril Collaborative Study). Arch Gen Psych 1988;45:789–96
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfield G, Singer J et al. Clozapine for the treatment-resistant schizophrenic; results of a US multicenter trial, Psychopharmacol 1989;99:560–63
   Google Scholar
• Meltzer HY et al. A prospective study of clozapine in treatment resistant schizophrenia patients. Psychopharmacol 1989;99(Suppl): 568–72
   Google Scholar
• Meltzer HY et al. Dimensions of outcomes with clozapine. Br J Psych 1992;160(Suppl 17):46–53
   Google Scholar
• Change in clozapine monitoring requirements. Phar J 1995;May 6:254–612
   Google Scholar
• Frankenburge FR, Zanarini MC. Comp Psych 1993;34(6), Nov/Dec
   Google Scholar
• Steinert T, Schmidt-Michel PO, Kaschka WP. Considerable improvement in a case of obsessive–compulsive disorder in an emotionally unstable personality disorder, borderline type under treatment with clozapine: Pharmacopsych 1996;29(3):111–4
   Google Scholar
• Chengappa KN, Ebeling T, Kang JS, Levine J, Parepally H. Clozapine reduces severe self–mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psych 1999;60(7):477–84
   Web of Science ®Google Scholar
• Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psych 1998;59(3):103–7
   Web of Science ®Google Scholar
• The Bethlem & Maudsley NHS Trust Prescribing Guidelines, 1999
   Google Scholar
• Tandon R, Goldman R. Positive and negative symptoms during clopazine treatment in schizophrenia. J Psych Res 1993;Oct-Dec:341–7
   Google Scholar
• Lieberman JA, Safferman AZ, Pollack S et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psych 1994;151:1744–52
   PubMed Web of Science ®Google Scholar
• Breier A, Buchanan RW, Kirkpatric B et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psych 1994;151:20
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Clozapine: is another view valid? Am J Psych 1995;152:821–5
   PubMed Web of Science ®Google Scholar
• Singer and Law. A double blind comparison of clozapine and chlorpromazine in schizophrenia of acute symptomatology. J Int Med 1974;2:433–5
   Google Scholar
• Gelenberg AJ, Doller JC. Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double-blind study. J Clin Psych 1979;40(5):238–40
   Web of Science ®Google Scholar
• Claghorn J, Honigfeld G, Abuzzahab FS Sr, Wang R, Steinbook R, Tuason V, Klerman G. The risk and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987:7(6);377–84
   Google Scholar
• Conley RR. Optimizing treatment with clozapine. J Clin Psych 1998;59(Suppl 3):44–8
   Google Scholar
• Lieberman JA. Maximizing clozapine therapy: managing side effects. J Clin Psych 1998;59(Suppl 3):38–43
   Google Scholar
• Baldessarini RJ, Frankenburg FR. A novel antipsychotic agent. New Engl J Med 1991;324(11):746–54
   PubMed Web of Science ®Google Scholar
• UK clozapine study group. The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK. Br J Psych 1993;150–54
   PubMed Web of Science ®Google Scholar
• Breier A. Buchanan RW. Kirkpatrick B. Davis OR. Irish D. Summerfelt A. Carpenter WT Jr. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psych 1994;151(1):20–6
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Burnett S, Bastani B, Ramirez LF. Effects of six months of clozapine treatment on the quality of life of chronic schizo-phrenic patients. Hosp Comm Psych 1990;41:892–7
   PubMedGoogle Scholar
• Avnon M. Rabinowitz J. Effectiveness of clozapine in hospitalized people with chronic schizophrenia. Br J Psych 1996;167(6):760–64
   Google Scholar
• Grace J, Bellus SB, Raulin ML, Herz MI, Priest BL, Brenner V, Donnelly K, Smith P, Gunn S. Long term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psych Servs 1996;47(1):41–5
   Google Scholar
• Maier GJ. The impact of clozapine on 25 forensic patients. Bull Am Acad Psych Law 1992,20(3),297–307
   PubMedGoogle Scholar
• Wilson WH. Clinical review of clozapine treatment in state hospital. Hosp Commun Psych 1992,43(7):700–03
   PubMedGoogle Scholar
• Volavka J. The effects of clozapine on aggression and substance abuse in schizophrenic patients. J Clin Psych 1999. 60(Suppl 12):43–6
   Google Scholar
• Chiles JA, Davidson P, McBride D. Effects of clozapine in the use of seclusion and restraint in a state hospital. Hosp Commun Psych. 1994;45(3):269–71
   PubMedGoogle Scholar
• Ebrahim GM, Gibler B, Gacono CB, Hayes G. Patient response to clozapine in a forensic psychiatric hospital. Hosp. Comm. Psych. 1994;45(3):271–3
   PubMedGoogle Scholar
• Buckley P, Bartell J, Donenwirth K, Lee S, Torigoe F, Schulz SC. Violence and schizophrenia: clozapine as specific anti-aggressive agent. Bull Am Acad Psych Law 1995;23(4):607–11
   PubMedGoogle Scholar
• Spivak B et al. Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic treatment resistant schizophrenic patients. Clin Neuropharmacol 1997;20:442–6
   PubMed Web of Science ®Google Scholar
• Green AL et al. Clozapine for comorbid substance use disorder and schizophrenia; do patients with schizophrenia have a reward–deficiency syndrome that can be ameliorated by clozapine? Harvard Rev Psych,1999;6(Mar-Apr):287–96
   PubMed Web of Science ®Google Scholar
• Yovell Y, Opler LA. Clozapine reverses cocaine craving in a treatment resistant mentally ill chemical abuser: a case report and a hypothesis. J Nerv Ment Dis 1994;182(10):591–2
   PubMed Web of Science ®Google Scholar
• Buckley P, Thompson P, Way L, Meltzer HY. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy [see comments]. Am J Psych 1994;151(3):385–9
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Suicide and schizophrenia; clozapine and the InterSept study. J Clin Psych 1999;60(Suppl 12):47–50
   Google Scholar
• Walker AM, Lanza LL. Mortality in current and former users of clozapine. Epidemiology 1997;8(6):671–7
   PubMed Web of Science ®Google Scholar
• Suppes T, Phillips KA, Judd CR. Clozapine treatment of nonpsychotic rapid cycling bipolar disorder: a report of three cases. Biol Psych 1994;36(5):338–40
   Google Scholar
• Zarate CA Jr, Tohen M, Baldessarini RJ. Clozapine in severe mood disorder. J Clin Psych 1995;56(9):411–7
   Web of Science ®Google Scholar
• McElroy SL. Clozapine in the treatment of psychotic mood disorders, schizo-effective disorder and schizophrenia. J Clin Psych 1991;52:411–4
   Web of Science ®Google Scholar
• The Parkinson’s Study Group. Low dose clozapine for the treatment of drug induced psychosis in Parkinson’s disease. New Engl J Med 1999;340:757–63
   PubMed Web of Science ®Google Scholar
• Fitton A, Benfield P. Clozapine and its pharmacoeconomic benefits in the treatment of schizophrenia. Pharm Econ. 1993 (August):31–56
   Google Scholar
• Baker RW, Chengappa KN, Baird JW, Steingard S, Christ MA, Schooler NR. Emergence of obsessive compulsive symptoms during treatment with clozapine [see Comments]. J Clin Psych 1992;53(12):439–42
   Web of Science ®Google Scholar
• Patil VJ. Development of transient obsessive– compulsive symptoms during treatment with clozapine. Am J Psych 1992;149:272
   PubMed Web of Science ®Google Scholar
• Zeilger J, Behar D. Clozapine induced priapism. Am J Psych 1992;149:272–3
   Web of Science ®Google Scholar
• Rosen SL, Hanno PM. Clozapine induced priapism. J Urol 1992;148(Sept):876–7
   PubMed Web of Science ®Google Scholar
• Stoppe G. Life threatening allergic reaction to clozapine. Br J Psych 1992;161:259–61
   PubMed Web of Science ®Google Scholar
• Wickert WA, Campbell NR, Martin L. Acute severe adverse clozapine reaction resembling systemic lupus erythematosus. Postgrad Med J 1994;70 (830):940–41
   PubMed Web of Science ®Google Scholar
• Martin A. Acute pancreatitis associated with clozapine use [Letter]. Am J Psych 1992;149:714
   PubMed Web of Science ®Google Scholar
• Kellner M, Wiedemann K, Krieg JC, Berg PA. Toxic hepatitis by clozapine treatment [Letter] [see Comments]. Am J Psych 1993;150(6):985–6
   PubMed Web of Science ®Google Scholar
• Kirson JL. Severe elevation in serum creatinine kinase associated with clozapine [Letter]. J Clin Psychopharm 1995;15(4):287–8
   PubMedGoogle Scholar
• Koval MS. Diabetic ketoacidosis associated with clozapine treatment. Am J Psych 1994;151:1520–21
   PubMed Web of Science ®Google Scholar
• Kamran A. Severe hyperglycaemia with high doses of clozapine. Am J Psych 1994;151:1395
   PubMed Web of Science ®Google Scholar
• Ghaeli P, Dufresne RL. Elevated serum triglycerides with clozapine resolved with risperidone in four patients. Pharmacother 1999;19(9):1099–101
   PubMed Web of Science ®Google Scholar
• Dursun SM, Szemis A, Andrews H, Reveley MA. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. J Psych Neurosci 1999;24(5):453–5
   PubMed Web of Science ®Google Scholar